Abstract: A method for altering the immunoregulatory system of humans and animals by administering a compound of the formula: ##STR1## wherein X.sub.3 is equal to X, X.sub.4, or X.sub.5 wherein X.sub.4 is fluoro, chloro, bromo or iodo, and X.sub.5 is mono-, di- or trihalomethyl, mono-, di or trifluoroethyl, perfluoropropyl, and wherein X is alkyl of from 1 to 3 carbon atoms, inclusive, 2-propynyl and 2-propenyl, and X.sub.1 is as defined in the specification.
Abstract: 6-Aryl pyrimidinol compounds, also can be named 6-aryl pyrimidinone or 6-aryl-isocytosine novel compounds, also novel and old compounds useful for treating viral infections and inducing interferon production. Dosage forms and method of treatment are disclosed.
Type:
Grant
Filed:
January 21, 1993
Date of Patent:
July 18, 1995
Assignee:
The Upjohn Company
Inventors:
Wendell Wierenga, Harvey I. Skulnick, Dale A. Stringfellow
Abstract: Novel 1,2,3-thiadiazole compounds, new and old 1,2,3-thiadiazole compositions and method of anti-thrombotic treatment are systemically administered to a human or animal.
Type:
Grant
Filed:
June 4, 1987
Date of Patent:
March 24, 1992
Assignee:
The Upjohn Company
Inventors:
Edward W. Thomas, Ronald H. Rynbrandt, deceased
Abstract: A method for treating bacterial or protozoal humans and animals by administering a 6-aryl pyrimidine compound or a salt thereof in association with a pharmaceutical carrier.
Abstract: A process for treating Herpes Type II virus by the systemic administration or topical application of ibuprofen (p-isobutylhydratropic acid) or a salt or ester thereof. Dosage forms are also disclosed.
Abstract: A method for treating aplastic anemia by systemic administration of a 6-aryl pyrimidine compound or a pharmaceutically acceptable salt thereof in association with a pharmaceutical carrier to a human or animal having aplastic anemia.
Abstract: This invention relates to a new method of therapy comprising the administration of a pro-drug to a human or animal, said pro-drug being a compound formed by a therapeutic compound chemically combined with another moiety by a photocleavable bond and irradiating the diseased area with ultraviolet radiation in an amount sufficient to cleave the bond and release the therapeutic compound in a therapeutically effective amount. Specifically disclosed are pro-drugs which are cleaved to therapeutically active medications which are anti-proliferative and anti-inflammatory compounds and the treatment of inflammatory and/or proliferative skin diseases therewith.
Type:
Grant
Filed:
May 30, 1984
Date of Patent:
May 20, 1986
Assignees:
The Upjohn Company, Regents of the University of Michigan
Abstract: A method for altering the immunoregulatory system of humans and animals by administering a 6 aryl pyrimidine compound or a salt thereof in association with a pharmaceutical carrier.
Abstract: Therapeutic process for treating panic disorders in humans comprising, the systemic administration of a 8-chloro-1-[(dimethylamino)-methyl]-6-phenyl-4H-s-triazolo[4,3-a][1,4]benz odiazepine including the N-oxides and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier.
Abstract: Therapeutic process for treating panic disorders in humans comprising, the systemic administration of a 1-methyl-6-phenyl-8-chloro-4H-s-triazolo[4,3-a][1,4]benzodiazepine including the N-oxides and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier.
Abstract: An improved process for the management of pain by concommittant administration of narcotic analgesics and flurbiprofen or salt or ester thereof. Process for reducing dosage and dosage forms are disclosed.
Abstract: Therapeutic process for treating panic disorders in humans comprising, the systemic administration of a 6-phenyl-8-chloro-4H-s-triazolo[4,3-a][1,4]benzodiazepine including the N-oxides and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier.
Abstract: Therapeutic compositions for treating humans and animals comprising, in dosage unit form, a 8-Chloro-1-hydroxymethyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine compound of the formula ##STR1## including the N-oxides, esters, and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier. The compositions are useful as soporifics and provide a process for inducing sleep.
Abstract: A process for treating Herpes Type II virus by the systemic administration or topical application of flurbiprofen (3-fluoro-4-phenylhydratropic acid) or a salt or ester thereof. Dosage forms are also disclosed.
Abstract: Therapeutic process for treating panic disorders in humans comprising the systemic administration of a 8-chloro-1-R-oxymethyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine of the formula ##STR1## wherein R is hydrogen, alkyl of from 1 to 3 carbon atoms, inclusive, ##STR2## wherein n is 0 to 16, inclusive, and m is 1 to 16 inclusive, including the N-oxides, esters, and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier.
Abstract: A process for treating Herpes Type I virus by the systemic administration or topical application of flurbiprofen (3-fluoro-4-phenylhydratropic acid) or a salt or ester thereof. Dosage forms are also disclosed.
Abstract: A class of 4-amine-4-arylcyclohexanones, their ketals, and acid addition salts have been synthesized and found to be useful for relieving pain in animals. Their analgesic activity appears to be of high order, and in addition some exhibit narcotic antagonist activity that is useful in modifying the cardiovascular, respiratory, and behavioral depression caused by other analgesics. Several show mixed analgesic and narcotic antagonist activity. Preferred compounds of the class are 4-(m-hydroxyphenyl)-4-dimethylaminocyclohexanone ethylene ketal, and 4-(m-hydroxyphenyl)-4-(n-butylmethylamino)cyclohexanone ethylene ketal as free bases and as their hydrochloride salts.Processes for synthesis and intermediates are described. Unit dosage forms and therapeutic treatments are disclosed.
Abstract: Novel compounds of the formula: ##STR1## wherein R.sub.1 is a variable consisting of hydrogen, alkyl of from 1 to 8 carbon atoms, CH.sub.2 -alkenyl wherein alkenyl is from 2 to 4 carbon atoms, inclusive, cycloalkyl of from 3 to 6 carbon atoms, inclusive, cycloalkylmethyl of from 3 to 6 carbon atoms, inclusive; R.sub.2 is a variable consisting of hydrogen, alkyl of from 1 to 8 carbon atoms, inclusive, with the proviso that R.sub.1 and R.sub.2 cannot both be hydrogen at the same time; Y is a variable consisting of alkyl of from 1 to 4 carbon atoms, inclusive, halogen, trifluoromethyl, hydroxy, alkanoyloxy from 2 to 5 carbon atoms, inclusive, alkoxy of from 1 to 4 carbon atoms, inclusive, cycloalkyloxy of from 3 to 6 carbon atoms, inclusive, benzyloxy; m is an integer 0, 1, 2; R.sub.5 is a variable consisting of hydrogen and alkyl of from 1 to 4 carbon atoms, inclusive; R.sub.3 is a variable consisting of alkyl of from 1 to 4 carbon atoms, inclusive; R.sub.
Abstract: A process for treating adult respiratory distress syndrome by the systemic administration of ibuprofen (p-isobutylhydratropic acid) or a salt or ester thereof. Dosage forms are also disclosed.
Abstract: Therapeutic compositions for treating humans and animals comprising, in dosage unit form, a 8-chloro-1-methanol-6-(o-chlorophenyl)-4H-s-triazolo[4,3-a][1,4]-benzodiaz epine compound of the formula: ##STR1## Including the N-oxides and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier. The compositions are useful as soporifics and provide a process for inducing sleep.